GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT05714839
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4129
- Registration Number
- NCT05705440
- Locations
- 🇹🇭
GSK Investigational Site, Muang, Thailand
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT05682326
- Locations
- 🇰🇷
GSK Investigational Site, Yangsan Gyeongnam, Korea, Republic of
Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT05677347
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT05660265
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 250
- Registration Number
- NCT05648357
- Locations
- 🇮🇳
GSK Investigational Site, Varanasi, Uttar Pradesh, India
Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1004
- Registration Number
- NCT05630859
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 941
- Registration Number
- NCT05630807
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh City, Vietnam
A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 382
- Registration Number
- NCT05630833
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 801
- Registration Number
- NCT05630846
- Locations
- 🇹🇷
GSK Investigational Site, Kocaeli, Turkey